Medtronic (MDT) shares have risen 6% since its last earnings report, outperforming the S&P 500; however, consensus estimates have since trended downward by 6.38%, leading to a Zacks Rank #4 (Sell) rating and expectations of below-average returns in the coming months. In comparison, Phibro Animal Health (PAHC), another stock in the same industry, has gained 4.1% over the past month, with strong revenue and EPS growth reported, earning it a Zacks Rank #1 (Strong Buy).
Medtronic (MDT) shares have appreciated approximately 6% since its last earnings report, outperforming the S&P 500. However, this recent stock strength contrasts sharply with a deteriorating analyst outlook, evidenced by a significant -6.38% downward revision in the consensus estimate over the past month. Medtronic's current VGM Scores (Growth B, Momentum F, Value C, Overall C) reflect a mixed fundamental picture, with the 'F' for Momentum being particularly concerning despite the recent price gains. Consequently, Medtronic carries a Zacks Rank #4 (Sell), signaling an expectation of below-average returns in the near term due to these downward estimate revisions. In contrast, Phibro Animal Health (PAHC), a peer in the Zacks Medical - Products industry, has also seen a 4.1% share price increase over the past month, supported by strong reported results for the quarter ended March 2025, including a 32.1% year-over-year revenue increase to $347.8 million and EPS more than doubling to $0.63 from $0.31. Phibro maintains a Zacks Rank #1 (Strong Buy) and a VGM Score of A, indicating a more favorable outlook despite a minor -0.5% change in its consensus estimate over the last 30 days.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
